Trial Profile
Phase I study of DK049 in tumour patients
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2024
Price :
$35
*
At a glance
- Drugs DK 049 (Primary)
- Indications Tumours
- Focus Adverse reactions
- Sponsors LadRx Corporation
- 09 Jan 2024 According to LadRx Corporation media release, the company has produced sufficient amount of LADR-7 under Good Manufacturing Practices (GMP) to initiate this study.
- 09 Jan 2024 According to LadRx Corporation media release, the company plans to fill IND to FDA FDA by the end of the third quarter of 2024 or the beginning of the fourth quarter of 2024 and first-patient dosing with LADR-7 by the end of 2024.
- 05 Jan 2016 According to CytRx media release, DK049 is expected to enter clinical trials in 2016.